Orchestra BioMed Holdings (OBIO) AI Stock Analysis

• Market Cap: $243.93M
• Dividend Yield: N/A
• Average Volume (3M): 323.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.06
• Revenue Growth: 6.46%
• EPS Growth: -14.32%
• Country: US
• Employees: 70
• Sector: N/A
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 56,464,730
• 10 Day Avg. Volume: 266,849
• 30 Day Avg. Volume: 323,035
• PEG Ratio: -0.20
• Price to Book (P/B): 4.47
• Price to Sales (P/S): 55.83
• P/FCF Ratio: -2.90
• Enterprise Value/Market Cap: 0.35
• Enterprise Value/Revenue: 30.28
• Enterprise Value/Gross Profit: 32.55
• Enterprise Value/Ebitda: -1.14
• 1Y Price Target: $12.50
• Price Target Upside: 276.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $4.50 ▲(35.54% Upside)

Orchestra BioMed's overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and negative profit margins. However, positive corporate events, including strategic partnerships and significant financing, provide a strong foundation for future growth. The technical analysis presents a mixed outlook, while valuation remains a concern due to unprofitability.

Orchestra BioMed Holdings Business Overview & Revenue Model

Company Description

Orchestra BioMed Holdings (OBIO) is a biomedical company focused on developing and commercializing innovative solutions to address significant unmet medical needs in the fields of cardiovascular disease and other chronic conditions. The company leverages its proprietary technology platforms to create advanced therapeutic devices, with a core emphasis on enhancing the efficacy and safety of existing treatments. OBIO's flagship products include the Virtue® Sirolimus-Eluting Balloon, aimed at treating peripheral artery disease, and various other devices designed to improve patient outcomes through minimally invasive procedures.

How the Company Makes Money

Orchestra BioMed generates revenue primarily through the commercialization of its medical devices and therapeutic solutions. The company earns money by selling its proprietary products, such as the Virtue® Sirolimus-Eluting Balloon, to healthcare providers and hospitals. Additionally, OBIO may engage in strategic partnerships with larger healthcare companies to co-develop or market its products, which can also provide financial support through upfront payments, milestone payments, and royalties on future sales. The company focuses on expanding its market reach and enhancing its product offerings, which are significant factors contributing to its earnings potential.

Orchestra BioMed Holdings Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Orchestra BioMed Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Neutral. The current price of 3.32 is below the 20-day moving average (MA) of 4.52, below the 50-day MA of 4.26, and above the 200-day MA of 3.30, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.09 is Neutral, neither overbought nor oversold. The STOCH value of 44.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OBIO.

Orchestra BioMed Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
OBIO	55 Neutral	$243.93M	-2.38	-166.97%	―	6.46%	-14.32%
CRDF	47 Neutral	$213.53M	-3.99	-102.71%	―	-27.29%	16.40%
PYXS	47 Neutral	$69.11M	-0.70	-87.28%	―	-82.53%	-52.00%
CLYM	41 Neutral	$336.15M	-6.57	-25.65%	―	―	64.81%
CGTX	41 Neutral	$128.00M	-3.05	-109.73%	―	―	50.39%

Orchestra BioMed Holdings Corporate Events

Orchestra BioMed Secures FDA Breakthrough Designation

On November 12, 2025, Orchestra BioMed Holdings held a conference call to discuss significant business updates, including clinical, strategic, and financing developments. The company highlighted its recent achievements, such as raising nearly $150 million in capital, strengthening collaborations with Medtronic, and securing FDA Breakthrough Device Designation for AVIM Therapy. These developments position Orchestra BioMed optimally to complete pivotal trials and advance its therapies towards regulatory approvals, enhancing its market position and potential profitability.

Orchestra BioMed Secures $147M for Therapy Advancements

In October 2025, Orchestra BioMed Holdings announced securing over $147 million in strategic-driven financing since August 2025, aimed at advancing their high-impact therapies like AVIM Therapy and Virtue SAB. The company is leveraging partnerships to accelerate clinical development and expects this funding to support operations through key milestones into Q4 2027, indicating a strong future market position and potential profitability in the cardiovascular treatment sector.

Orchestra BioMed Announces Strategic Agreement with Terumo

On October 28, 2025, Orchestra BioMed Holdings announced a new strategic agreement with Terumo Corporation, which includes a $30 million investment and grants Terumo a right of first refusal for the Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) for coronary artery disease treatment. This agreement supersedes a prior distribution agreement and highlights the clinical and commercial potential of Virtue SAB, as well as providing Orchestra BioMed with additional capital to advance its pivotal stage programs. The company also initiated patient enrollment for its Virtue Trial in the U.S., aiming to support regulatory approval for the Virtue SAB, which has shown promising results in previous studies and has FDA Breakthrough Device Designation.